|
목적 : To determine the factors for predicting a favorable response to intravitreal bevacizumab (IVB) for branch retinal vein occlusion-associated macular edema (BRVO c ME)
방법 : A total of 37 patients first diagnosed with BRVO c ME and treated with IVB at least one more time were included in this retrospective study. Demographic data, initial best corrected visual acuity (BCVA), initial central macular thickness (CMT) and CMT after two injections were evaluated. IVB non-responders were defined as patients whose CMT was not decreased by more than 10% of initial CMT even after two IVB injections. Types of macular edema were subdivided into cystoid macular edema (CME) only, serous retinal detachment (SRD) only, and combined CME and SRD groups.
결과 : 33 patients were classified as responders and 4 patients were classified as non-responders. The responder group was comprised of significantly older ages than the non-responder group (63.78±11.70 vs 54.5±1.00, p=0.034, Mann Whitney test). Initial BCVA of the non-responder group was significantly higher than that of the responder group (0.08±1.04 vs 0.37±0.60, logMAR, p=0.003, Student t-test). The anatomical type of macular edema did not significantly influence the quality of response to IVB.
결론 : IVB could be more effective in treating older-aged patients who have BRVO c ME when considering the anatomical change of macula. For patients who have relatively good initial BCVA (more than 0.08, logMAR), IVB might not be the best first-line treatment for subsiding macular edema considering the cost-effectiveness of the treatment.
|